The median TMB was 1.92 (range = 0.37-16.99 variants/Megabase) in CHEK2-deficient cancers, which is comparable to cancers that developed in individuals heterozygous for CHEK2 gPVs (median TMB of 2.83 [range = 0.2-53 variants/Megabase]; Figure 1, C) and in line with the literature (9,10). This evidence concerns the gene CHEK2 and cancer.